Takanori Goi, Youhei Kimura, Katsuji Sawai, Mitsuhiro Morikawa, Kanji Katayama, Akio Yamaguchi
First Department of Surgery, University of Fukui, Fukui, Japan.
Case Rep Gastroenterol. 2011 Jan;5(1):95-9. doi: 10.1159/000324399. Epub 2011 Feb 5.
We report the case of a patient with colon cancer accompanied by multiple unresectable liver metastases who showed complete response (CR) to modified TEGAFIRI (mTEGAFIRI) (tegafur-uracil/leucovorin+irinotecan) chemotherapy. The patient was a 58-year-old Japanese male with cancer of the descending colon accompanied by multiple unresectable liver metastases. Following resection of the sigmoid colon cancer, mTEGAFIRI chemotherapy was administered. Abdominal computed tomography performed upon completion of 12 courses of chemotherapy showed that the unresectable liver metastatic lesions had disappeared, indicating CR. The only adverse drug reactions (ADRs) experienced to date have been stomatitis (grade 1) and neutropenia (grade 1). Anticancer therapy has thus been continued, and CR has been maintained for 15 months. The present patient achieved CR in response to mTEGAFIRI chemotherapy, a regimen that has not previously been reported, while experiencing only mild ADRs and maintaining a good quality of life. mTEGAFIRI chemotherapy is convenient to administer and is thought to be a potentially useful treatment option for patients with unresectable, recurrent colon cancer.
我们报告了一例伴有多处不可切除肝转移的结肠癌患者，该患者对改良的替吉奥氟尿嘧啶亚叶酸钙联合伊立替康（mTEGAFIRI）化疗表现出完全缓解（CR）。患者为一名58岁的日本男性，患有降结肠癌并伴有多处不可切除的肝转移。在乙状结肠癌切除术后，给予mTEGAFIRI化疗。完成12个疗程化疗后进行的腹部计算机断层扫描显示，不可切除的肝转移病灶已消失，表明达到CR。迄今为止经历的唯一药物不良反应（ADR）为口腔炎（1级）和中性粒细胞减少（1级）。因此继续进行抗癌治疗，CR已维持15个月。本患者对mTEGAFIRI化疗产生CR，这是一种此前未被报道过的治疗方案，同时仅经历轻度ADR且维持了良好的生活质量。mTEGAFIRI化疗给药方便，被认为是不可切除、复发性结肠癌患者潜在有用的治疗选择。
